Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on May 30, 2006

Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyl024
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/5/263    most recent
hyl024v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Byun, J. H.
Right arrow Articles by Lee, K. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Byun, J. H.
Right arrow Articles by Lee, K. Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 Foundation for Promotion of Cancer Research
Received October 12, 2005
Accepted February 8, 2006

Original Article

Association between Cyclooxygenase-2 and Matrix Metalloproteinase-2 Expression in Non-Small Cell Lung Cancer

Jae Ho Byun 1, Myung Ah Lee 1 *, Sang Young Roh 1, Byoung Yong Shim 1, Sook Hee Hong 1, Yoon Ho Ko 1, Su Jin Ko 1, In Sook Woo 1, Jin Hyoung Kang 1, Young Seon Hong 1, Kyung Shik Lee 1, Ah Won Lee 2, Gyeong Sin Park 2, and Kyo Yeong Lee 2

1 Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
2 Department of Clinical Pathology, College of Medicine, The Catholic University of Korea, Seoul, South Korea

* To whom correspondence should be addressed.
Myung Ah Lee, E-mail: angelamd{at}catholic.ac.kr


   Abstract

Background: Cyclooxygenase-2 (COX-2) contributes to invasiveness of cancer through activation of several matrix metalloproteinases (MMPs). Matrix metalloproteinase-2 (MMP-2) is a proteolytic enzyme that degrades the extracellular matrix, and has been linked to invasion and metastasis. This study aims to assess the correlation of the COX-2 expression and the MMP-2 expression in patients with non-small cell lung cancer (NSCLC).

Methods: We analyzed the protein expressions of COX-2 and MMP-2 by immunohistochemical staining on the tissue array specimens from 204 patients with completely resected NSCLC. A <10% immunostaining of the cancer cells was considered negative, while >10% was considered positive.

Results: The COX-2 expression was positive in 68.1% and that of the MMP-2 was positive in 45.6%. The positive expression rate of MMP-2 (52.5%) in the positive COX-2 group was higher than that in the negative COX-2 group (30.8%, P = 0.004). Furthermore, the MMP-2 expression was associated with lymph node involvement, the tumor stage and the histological type. The patients with a positive MMP-2 expression showed a reduced survival (P = 0.048).

Conclusions: The COX-2 expression is associated with the MMP-2 expression in NSCLC patients: the latter may also be associated with tumor progression and reduced survival in NSCLC patients.

Keywords: cyclooxygenase-2; matrix metalloproteinase-2; non-small cell lung cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
D. Dhawan, A. B. Jeffreys, R. Zheng, J. C. Stewart, and D. W. Knapp
Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells
Mol. Cancer Ther., April 1, 2008; 7(4): 897 - 904.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.